[{"orgOrder":0,"company":"OPKO Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Calcifediol","moa":"Vitamin D3 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"OPKO Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"OPKO Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OPKO Health \/ Inapplicable"},{"orgOrder":0,"company":"OPKO Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Calcifediol","moa":"Vitamin D3 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"OPKO Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"OPKO Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OPKO Health \/ Inapplicable"},{"orgOrder":0,"company":"OPKO Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Calcifediol","moa":"Vitamin D3 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"OPKO Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"OPKO Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OPKO Health \/ Inapplicable"},{"orgOrder":0,"company":"OPKO Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Calcifediol","moa":"Vitamin D3 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"OPKO Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"OPKO Health \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"OPKO Health \/ Inapplicable"},{"orgOrder":0,"company":"OPKO Health","sponsor":"VFMCRP","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Calcifediol","moa":"Vitamin D3 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"OPKO Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"OPKO Health \/ VFMCRP","highestDevelopmentStatusID":"15","companyTruncated":"OPKO Health \/ VFMCRP"},{"orgOrder":0,"company":"OPKO Health","sponsor":"Vifor Pharma","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Termination","leadProduct":"Calcifediol","moa":"Vitamin D3 receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"OPKO Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"OPKO Health \/ Vifor Pharma","highestDevelopmentStatusID":"15","companyTruncated":"OPKO Health \/ Vifor Pharma"},{"orgOrder":0,"company":"OPKO Health","sponsor":"HealthCare Royalty","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Agreement","leadProduct":"Somatrogon","moa":"STAT5b signalling pathway","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"OPKO Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OPKO Health \/ HealthCare Royalty","highestDevelopmentStatusID":"15","companyTruncated":"OPKO Health \/ HealthCare Royalty"},{"orgOrder":0,"company":"OPKO Health","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Somatrogon","moa":"STAT5b signalling pathway","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"OPKO Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OPKO Health \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"OPKO Health \/ Pfizer Inc"},{"orgOrder":0,"company":"OPKO Health","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Somatrogon","moa":"STAT5b signalling pathway","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"OPKO Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OPKO Health \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"OPKO Health \/ Pfizer Inc"},{"orgOrder":0,"company":"OPKO Health","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Somatrogon","moa":"STAT5b signalling pathway","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"OPKO Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OPKO Health \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"OPKO Health \/ Pfizer Inc"},{"orgOrder":0,"company":"OPKO Health","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Somatrogon","moa":"STAT5b signalling pathway","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"OPKO Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OPKO Health \/ Pfizer Inc","highestDevelopmentStatusID":"15","companyTruncated":"OPKO Health \/ Pfizer Inc"},{"orgOrder":0,"company":"ModeX Therapeutics","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ModeX Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Buccal","sponsorNew":"ModeX Therapeutics \/ BARDA","highestDevelopmentStatusID":"4","companyTruncated":"ModeX Therapeutics \/ BARDA"},{"orgOrder":0,"company":"ModeX Therapeutics","sponsor":"OPKO Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody","year":"2022","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ModeX Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Nasal Inhalation","sponsorNew":"ModeX Therapeutics \/ OPKO Health","highestDevelopmentStatusID":"4","companyTruncated":"ModeX Therapeutics \/ OPKO Health"},{"orgOrder":0,"company":"ModeX Therapeutics","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Funding","leadProduct":"MDX2202","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"ModeX Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ModeX Therapeutics \/ BARDA","highestDevelopmentStatusID":"4","companyTruncated":"ModeX Therapeutics \/ BARDA"},{"orgOrder":0,"company":"OPKO Health","sponsor":"Leader Medical","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Agreement","leadProduct":"OPK88003","moa":"GLP-1 receptor","graph1":"Endocrinology","graph2":"Phase II","graph3":"OPKO Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"OPKO Health \/ Leader Medical","highestDevelopmentStatusID":"8","companyTruncated":"OPKO Health \/ Leader Medical"},{"orgOrder":0,"company":"OPKO Health","sponsor":"CAMP4 Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"OPK88001","moa":"SCN1A","graph1":"Neurology","graph2":"Preclinical","graph3":"OPKO Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OPKO Health \/ CAMP4 Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"OPKO Health \/ CAMP4 Therapeutics"},{"orgOrder":0,"company":"OPKO Health","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2025","type":"Inapplicable","leadProduct":"V350A","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"OPKO Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"OPKO Health \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"OPKO Health \/ Merck & Co"},{"orgOrder":0,"company":"OPKO Health","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Vaccine","year":"2023","type":"Collaboration","leadProduct":"MDX-2201","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"OPKO Health","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OPKO Health \/ Merck & Co","highestDevelopmentStatusID":"5","companyTruncated":"OPKO Health \/ Merck & Co"},{"orgOrder":0,"company":"OPKO Health","sponsor":"EnteraBio Ltd","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2025","type":"Collaboration","leadProduct":"Oxyntomodulin Analog","moa":"GCGR\/GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"OPKO Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"OPKO Health \/ EnteraBio Ltd","highestDevelopmentStatusID":"4","companyTruncated":"OPKO Health \/ EnteraBio Ltd"}]

Find Clinical Drug Pipeline Developments & Deals by OPKO Health

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          MAGHREB PHARMA
                          Not Confirmed
                          MAGHREB PHARMA
                          Not Confirmed

                          Details : The collaborations aims to advance the oral dual agonist GLP-1/glucagon peptide OPK-88006 (oxyntomodulin analog) as a once-daily tablet treatment for patients with obesity.

                          Product Name : OPK-88006

                          Product Type : Peptide

                          Upfront Cash : Undisclosed

                          March 19, 2025

                          Lead Product(s) : Oxyntomodulin Analog

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Preclinical

                          Sponsor : EnteraBio Ltd

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          MAGHREB PHARMA
                          Not Confirmed
                          MAGHREB PHARMA
                          Not Confirmed

                          Details : V350A is a vaccine candidate based on MDX2201 ferritin nanoparticle vaccine platform, being investigated for the treatment of epstein-barr virus infection.

                          Product Name : V350A

                          Product Type : Vaccine

                          Upfront Cash : Inapplicable

                          January 07, 2025

                          Lead Product(s) : V350A

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I

                          Sponsor : Merck & Co

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          MAGHREB PHARMA
                          Not Confirmed
                          MAGHREB PHARMA
                          Not Confirmed

                          Details : OPKO retained a significant portion of Ngenla (somatrogon) through the agreement. It is an approved product, which is indicated for pediatric patients with growth hormone deficiency.

                          Product Name : Ngenla

                          Product Type : Other Large Molecule

                          Upfront Cash : Undisclosed

                          July 17, 2024

                          Lead Product(s) : Somatrogon

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved FDF

                          Sponsor : HealthCare Royalty

                          Deal Size : $250.0 million

                          Deal Type : Agreement

                          blank

                          04

                          MAGHREB PHARMA
                          Not Confirmed
                          MAGHREB PHARMA
                          Not Confirmed

                          Details : The funding will support the development of a novel multispecific antibody to SARS-CoV-2 from preclinical and influenza multispecifics with gene and/or protein delivery modalities.

                          Product Name : MDX2202

                          Product Type : Other Large Molecule

                          Upfront Cash : Undisclosed

                          July 10, 2024

                          Lead Product(s) : MDX2202

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : BARDA

                          Deal Size : $110.0 million

                          Deal Type : Funding

                          blank

                          05

                          MAGHREB PHARMA
                          Not Confirmed
                          MAGHREB PHARMA
                          Not Confirmed

                          Details : The agreement aims to advance a platform and specific candidates addressing a range of viral infectious diseases and will enable research, development and clinical evaluation of potent multispecific antibodies, based on ModeX proprietary MSTAR technology...

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          September 28, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Discovery

                          Sponsor : BARDA

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          06

                          MAGHREB PHARMA
                          Not Confirmed
                          MAGHREB PHARMA
                          Not Confirmed

                          Details : ModeX and Merck will jointly advance MDX-2201 to an IND application filing, after which Merck will be responsible for clinical and regulatory activities and product commercialization. MDX-2201 leverages ModeX’s innovative biologics platform to target m...

                          Product Name : MDX-2201

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          August 03, 2023

                          Lead Product(s) : MDX-2201

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : IND Enabling

                          Sponsor : Merck & Co

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          07

                          MAGHREB PHARMA
                          Not Confirmed
                          MAGHREB PHARMA
                          Not Confirmed

                          Details : ModeX Therapeutics has developed highly flexible multi-specific antibody technology platforms with broad targeting and functional capabilities, simpler manufacturing and potentially better specificity and safety, providing significant differentiation fro...

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          September 05, 2022

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Preclinical

                          Sponsor : OPKO Health

                          Deal Size : $300.0 million

                          Deal Type : Acquisition

                          blank

                          08

                          MAGHREB PHARMA
                          Not Confirmed
                          MAGHREB PHARMA
                          Not Confirmed

                          Details : RAYALDEE extended-release capsules are indicated for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.

                          Product Name : Rayaldee

                          Product Type : Vitamins/Minerals/Inorganic Salts

                          Upfront Cash : Inapplicable

                          March 02, 2022

                          Lead Product(s) : Calcifediol

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved FDF

                          Sponsor : VFMCRP

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          MAGHREB PHARMA
                          Not Confirmed
                          MAGHREB PHARMA
                          Not Confirmed

                          Details : CAMP4 is pioneering a novel approach to programmable therapeutics that combines a deep understanding of regulatory RNA and gene expression with a complementary and customizable oligonucleotide modality.

                          Product Name : OPK88001

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          December 07, 2021

                          Lead Product(s) : OPK88001

                          Therapeutic Area : Neurology

                          Highest Development Status : Preclinical

                          Sponsor : CAMP4 Therapeutics

                          Deal Size : $93.5 million

                          Deal Type : Licensing Agreement

                          blank

                          10

                          MAGHREB PHARMA
                          Not Confirmed
                          MAGHREB PHARMA
                          Not Confirmed

                          Details : Somatrogon is an investigational biologic product that is glycosylated and comprises amino acid sequence of human growth hormone and one copy of C-terminal peptide from beta chain used for treatment of growth hormone deficiency (GHD) in pediatric patient...

                          Product Name : Ngenla

                          Product Type : Other Large Molecule

                          Upfront Cash : Inapplicable

                          September 24, 2021

                          Lead Product(s) : Somatrogon

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase III

                          Sponsor : Pfizer Inc

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank